A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2017
At a glance
- Drugs BPN 14770 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Tetra Discovery Partners
- 19 Dec 2016 According to a Tetra Discovery Partners media release, this trial was conducted with the support of the National Institute of Health through a grant from the National Institute on Aging (AG054243) and funding from the Alzheimer's Drug Discovery Foundation.
- 19 Dec 2016 Post hoc pooled results published in a Tetra Discovery Partners media release.
- 01 Apr 2016 Results published in a Tetra Discovery Partners media release.